Expired activity
Please go to the PowerPak homepage and select a course.

Understanding the Treatment Paradigm for Age-Related Macular Degeneration

This activity is jointly provided by Postgraduate Institute for Medicine and MedEdicus LLC and supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Release date:

November 18, 2019

Expiration date:

November 18, 2020

Estimated time to complete the activity:

1.5 hours


W. Lloyd Clark, MD (Co-Chair)
Assistant Clinical Professor of Ophthalmology
University of South Carolina School of Medicine
Retina Specialist, Palmetto Retina Center
Columbia, South Carolina

Winston Wong, PharmD (Co-Chair)
W-Squared Group
Longboat Key, Florida

Jeffrey S. Heier, MD
Co-President and Medical Director
Ophthalmic Consultants of Boston
Boston, Massachusetts

Gary Owens, MD
Gary Owens Associates
Ocean View, Delaware


Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


W. Lloyd Clark, MD
Consulting fees from Genentech, Inc; and Regeneron Pharmaceuticals, Inc

Fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speakers' bureaus) from Genentech, Inc; and Regeneron Pharmaceuticals, Inc

Contracted research from Genentech, Inc; and Regeneron Pharmaceuticals, Inc

Jeffrey S. Heier, MD
Consulting fees from Adverum; Apellis Pharmaceuticals; Bayer Corporation; Chengdu Kanghong Pharmaceutical Group Co, Ltd; Daiichi Sankyo Company, Limited; F. Hoffman-La Roche Ltd; Genentech, Inc; Hemera Biosciences; Notal Vision; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; SciFluor Life Sciences, Inc; Stealth BioTherapeutics Inc; and Tyrogenex

Contracted research from Aerpio Therapeutics; Apellis Pharmaceuticals; Corcept Therapeutics; Daiichi Sankyo Company, Limited; F. Hoffman-La Roche Ltd; Genentech, Inc; Genzyme Corporation; Hemera Biosciences; Janssen Global Services, LLC; Ophthotech Corporation; Optovue, Incorporated; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; SciFluor Life Sciences, Inc; and Tyrogenex

Ownership interest in Ocular Therapeutix, Inc

Gary Owens, MD
Dr Owens has nothing to disclose.

Winston Wong, PharmD
Dr Wong has nothing to disclose.

Peer Reviewer
Jordana G. Fein, MD, MS, has no relevant commercial relationships to disclose.

Planners and Managers
The PIM planners and managers have nothing to disclose. The MedEdicus planners and managers have nothing to disclose.


jointly accredited by (ACCME)In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and MedEdicus LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
UAN: JA4008162-9999-19-979-H01-P.

Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee for this educational activity.


This activity is intended for managed care clinical and nonclinical executives engaged in the care of patients with neovascular age-related macular degeneration (nAMD).


During the period November 18, 2019, through November 18, 2020, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer, then proceed to the next question. Once completed, click on Submit Posttest at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 75% or higher), your Statement of Credit will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 75%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


The goal of this activity is to foster better collaboration between payers and providers in the selection of the most optimal treatment regimens for patients with nAMD.


After completing this activity, the participant should be better able to:

  • Explain current practice patterns for the treatment of patients with nAMD
  • Outline the benefits of collaboration between payers and providers


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This CME/CE activity is copyrighted to MedEdicus LLC ©2019.
All rights reserved. 159